

3rd Lung MCMC (Multidisciplinary Cancer Management Course)

A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

DAY ONE - MARCH 24, 2018 (SATURDAY)

| | | |
|---------------|--|---|
| 08.00 – 08.50 | REGISTRATION | |
| 08.50 – 09.25 | Introductory Session | |
| 08.50 – 08.55 | Welcome Remarks | Navneet Singh |
| 08.55 – 09.10 | ASCO Presentations | Vanessa Sarchet |
| 09.10 – 09.22 | Epidemiology of Lung Cancer (Global & Indian) | JS Thakur |
| 09.22 – 09.25 | Discussion (Q & A) | |
| 09.25 – 09.40 | Welcome of delegates by PGIMER Director and Deans | |
| 09.40 – 10.55 | Session 1 (Diagnosis of Lung Cancer) | SK Jindal, A Rajwanshi, Mandeep Garg |
| 09.40 – 09.52 | Clinical features that lead to suspicion of lung cancer | KT Prasad |
| 09.52 – 09.55 | Discussion (Q & A) | |
| | Essentials of Imaging in Lung Cancer | |
| 09.55 – 10.05 | Radiological Imaging in Lung Cancer (CT Thorax; MRI Brain) | Nilendu Purandare |
| 10.05 – 10.15 | Nuclear Imaging in Lung Cancer (Bone Scan & PET/PET-CT) | Rajender Kumar |
| 10.15 – 10.20 | Discussion (Q & A) | |
| | Essentials of Pathological Testing in Lung Cancer | |
| 10.20 – 10.30 | Biopsy specimens | Amanjit Bal |
| 10.30 – 10.40 | FNAC, fluid specimens & cell blocks | Nalini Gupta |
| 10.40 – 10.50 | Molecular testing | Anuradha Choughule |
| 10.50 – 10.55 | Discussion (Q & A) | |
| 10.55 – 11.15 | TEA BREAK | |
| 11.15 – 12.00 | Session 2 (Staging of Lung Cancer) | R Agarwal, N Khandelwal, |
| 11.15 – 11.27 | Current TNM staging for lung cancer | <i>Ramon Rami-Porta</i> |
| 11.27 – 11.30 | Discussion (Q & A) | |
| | Mediastinal Staging Procedures in Lung Cancer | |
| 11.30 – 11.43 | Endoscopic staging (EBUS, EUS, EBUS + EUS) | Sahajal Dhooria |
| 11.43 – 11.56 | Invasive (surgical) staging (including mediastinoscopy) | Sabita Jiwnani |
| 11.56 – 12.00 | Discussion (Q & A) | |

3rd Lung MCMC (Multidisciplinary Cancer Management Course)

A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

DAY ONE - MARCH 24, 2018 (SATURDAY)

| | | |
|----------------------|--|--|
| 12.00 – 12.40 | Session 3 (Panel Discussion On Diagnosis And Staging) | |
| | Moderator: Anant Mohan Panelists: <ol style="list-style-type: none"> 1. Deepak Aggarwal (Pulmonology/Medical Oncology) 2. Anuradha Choughule (Pathology/Molecular Biology) 3. Deepali Jain (Pathology/Molecular Biology) 4. Nilendu Purandare (Imaging) 5. Inderpaul S. Sehgal (Pulmonology) 6. Harmandeep Singh (Nuclear Imaging) | |
| 12.45 – 13.30 | Industry Sponsored Satellite Symposium 1 (Boehringer Ingelheim): Optimizing the role of TKIs in the management of EGFR mutation positive NSCLC: Role of appropriate sequencing | |
| 12.45 – 12.50 | Introduction | Navneet Singh |
| 12.50 – 13.30 | Moderator: Ullas Batra Panelists: <ol style="list-style-type: none"> 1. Anuradha Choughule (Pathology/Molecular Biology) 2. Chandan Das (Medical Oncology) 3. Gautam Goyal (Medical Oncology) 4. Sumant Gupta (Medical Oncology) 5. Kunal Jain (Medical Oncology) 6. Prabhat Malik (Medical Oncology) | |
| 13.30 – 14.15 | LUNCH BREAK | |
| 14.15 – 15.00 | Session 4 (Early Stage NSCLC) | A Sood, Ashutosh N. Aggarwal, Sunil Kumar |
| 14.15 – 14.27 | Pre-operative evaluation and assessment for fitness for surgery | VK Arya |
| 14.27 – 14.30 | Discussion (Q & A) | |
| 14.30 – 14.42 | Principles of surgical management of early stage NSCLC (including importance of Complete Resection) | CS Pramesh |
| 14.42 – 14.45 | Discussion (Q & A) | |
| 14.45 – 14.57 | Management of medically inoperable early stage NSCLC (SBRT) | <i>Suresh Senan</i> |
| 14.57 – 15.00 | Discussion (Q & A) | |

3rd Lung MCMC (Multidisciplinary Cancer Management Course)

A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

DAY ONE - MARCH 24, 2018 (SATURDAY)

| | | |
|----------------------|---|----------------------------------|
| 15.00 – 15.40 | Session 5 (Multidisciplinary Tumor Board - Early Stage NSCLC) | |
| | Moderator: Sabita Jiwnani Panelists: <ol style="list-style-type: none"> 1. Ullas Batra (Medical Oncology) 2. Rakesh Kapoor (Radiation Oncology) 3. Anant Mohan (Pulmonology/Medical Oncology) 4. Ramon Rami Porta (Surgical Oncology) 5. Suresh Senan (Radiation Oncology) 6. Harkant Singh (Surgical Oncology) | |
| 15.40 – 16.00 | TEA BREAK | |
| 16.00 – 16.30 | Session 6 (Locally Advanced NSCLC) | Awadesh Pandey, R Kapoor, |
| 16.00 – 16.12 | Differentiating IIIA vs IIIB vs IIIC: Radiation Oncologist's perspective | Suresh Senan |
| 16.12 – 16.15 | Discussion (Q & A) | |
| 16.15 – 16.27 | Differentiating IIIA vs IIIB vs IIIC: Surgical Oncologist's perspective | Ramon Rami Porta |
| 16.27 – 16.30 | Discussion (Q & A) | |
| 16.30 – 17.10 | Session 7 (Multidisciplinary Tumor Board – Locally Advanced NSCLC) | |
| | Moderator: CS Pramesh Panelists: <ol style="list-style-type: none"> 1. Rakesh Chopra (Medical Oncology) 2. Sachin Gupta (Medical Oncology) 3. Rakesh Kapoor (Radiation Oncology) 4. Ramon Rami Porta (Surgical Oncology) 5. Suresh Senan (Radiation Oncology) 6. Anil Tibdewal (Radiation Oncology) | |
| 17.15 – 18.00 | Industry Sponsored Satellite Symposium 2 (Pfizer): Crizotinib in the management of ROS1 Positive NSCLC | |
| 17.15 – 17.20 | Introduction | D. Behera, Rajeev Seam |
| 17.20 – 17.40 | Crizotinib in the management of ROS1 Positive NSCLC | Tony Mok |

3rd Lung MCMC (Multidisciplinary Cancer Management Course)

A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

DAY ONE - MARCH 24, 2018 (SATURDAY)

| | | |
|----------------------|---|----------------|
| 17.40 – 18.00 | <p>Panel Discussion</p> <p>Moderator: Ullas Batra</p> <p>Panelists:</p> <ol style="list-style-type: none"> 1. Amanjit Bal (Pathology/Molecular Biology) 2. Rakesh Kapoor (Radiotherapy) 3. Prabhat Malik (Medical Oncology) 4. Kumar Prabhash (Medical Oncology) 5. Gaurav Prakash (Medical Oncology) 6. Jatin Sarin (Medical Oncology) | |
| 18.00 – 18.45 | <p>Industry Sponsored Satellite Symposium 3 (BMS):</p> <p>Indian Experience with Nivolumab in NSCLC</p> <p>Amit Agarwal (Chair)</p> | |
| 18.00 – 18.15 | Indian experience with Nivolumab in NSCLC | Kumar Prabhash |
| 18.15 – 18.25 | Indian experience with Nivolumab in NSCLC | Ullas Batra |
| 18.25 – 18.45 | <p>Moderator: Amit Agarwal</p> <p>Panelists:</p> <ol style="list-style-type: none"> 1. Ullas Batra (Medical Oncology) 2. Sachin Gupta (Medical Oncology) 3. Sumant Gupta (Medical Oncology) 4. Prabhat Malik (Medical Oncology) 5. Kumar Prabhash (Medical Oncology) | |
| 19:30 | <p>DINNER (Lawns of Hotel Mountview, Sector 10)</p> | |

3rd Lung MCMC (Multidisciplinary Cancer Management Course)

A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

DAY TWO - MARCH 25, 2018 (SUNDAY)

| | | |
|----------------------|--|---|
| 08.30 – 09.15 | Session 8 (Metastatic NSCLC with driver mutations/rearrangements) | Prasanta Mohapatra, D Behera, Gaurav Gupta |
| 08.30 – 08.45 | Biomarker Testing in Metastatic NSCLC (EGFR-ALK-ROS1; Others) | <i>Ming Tsao</i> |
| 08.45 – 08.50 | Discussion (Q & A) | |
| 08.50 – 09.10 | Precision Medicine for metastatic NSCLC with driver mutations/rearrangements (EGFR-ALK-ROS1; Others) | <i>Tony Mok</i> |
| 09.10 – 09.15 | Discussion (Q & A) | |
| 09.15 – 09.55 | Session 9 (Multidisciplinary Tumor Board – Metastatic NSCLC with driver mutations/rearrangements) | |
| | Moderator: Kumar Prabhash Panelists: <ol style="list-style-type: none"> 1. Amanjit Bal (Pathology/Molecular Biology) 2. Gautam Goyal (Medical Oncology) 3. Rajiv Kaushal (Pathology/Molecular Biology) 4. <i>Tony Mok</i> (Medical Oncology) 5. Navneet Singh (Pulmonology/Medical Oncology) 6. Anil Tibdewal (Radiation Oncology) | |
| 10.00 – 10.30 | Industry Sponsored Satellite Symposium 4 (Novartis): Rakesh Chopra (Chair) | |
| | Place of second generation ALK inhibitor in treatment landscape of NSCLC | <i>Tony Mok</i> |
| 10.30 – 10.50 | TEA BREAK | |
| 10.50 – 11.40 | Session 10 (Metastatic NSCLC without driver mutations/rearrangements) | Surendra Kumar Verma, Aditya Jindal, Rakesh Chopra |
| 10.50 – 11.02 | PD-L1 testing in lung cancer (Blueprint Project) | <i>Ming Tsao</i> |
| 11.02 – 11.05 | Discussion (Q & A) | |
| | Immune Check Point Inhibitor Therapy for stage IV NSCLC | |
| 11.05 – 11.20 | Principles of Immune Check Point Inhibitor Therapy | <i>Tony Mok</i> |
| 11.20 – 11.35 | Identifying & Managing Toxicities with Immune Check Point Inhibitors | Kumar Prabhash |
| 11.35 – 11.40 | Discussion (Q & A) | |

3rd Lung MCMC (Multidisciplinary Cancer Management Course)

A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

DAY TWO - MARCH 25, 2018 (SUNDAY)

| | | |
|----------------------|--|--------------------------------------|
| 11.40 – 12.25 | Session 11 (Multidisciplinary Tumor Board – Metastatic NSCLC without driver mutations/rearrangements) | |
| | Moderator: Ullas Batra Panelists: <ol style="list-style-type: none"> 1. Divyesh Anand (Radiation Oncology) 2. Prabhat S. Malik (Medical Oncology) 3. <i>Tony Mok</i> (Medical Oncology) 4. Sushmita Pathy (Palliative Care) 5. Kumar Prabhash (Medical Oncology) 6. <i>Ming Tsao</i> (Pathology/Molecular Biology) | |
| 12.30 – 13.15 | Industry Sponsored Satellite Symposium 5 (Astra Zeneca): 2L EGFR+ NSCLC: Controversies to consensus | |
| | Introduction | |
| 12.30 – 12.45 | The changing treatment paradigm after progression in advanced EGFR mutated lung cancer | <i>Tony Mok</i> |
| 12.45 – 12.55 | Do not rush for biopsy (tissue or ct DNA) on progression, Time to biopsy is critical for the right test results | Ullas Batra |
| 12.55 – 13.05 | Tissue biopsy – the gold standard after negative ct DNA | Kumar Prabhash |
| 13.05 – 13.15 | Tissue biopsy possible in most patients in 2L NSCLC | Amit Janu |
| 13.15 – 14.00 | LUNCH BREAK | |
| 14.00 – 14.45 | Session 12 (SCLC) | Rajeev Seam, Surender Kashyap |
| 14.00 – 14.12 | Treating SCLC using TNM staging: Does it make a difference? | Anil Tibdewal |
| 14.12 – 14.15 | Discussion (Q & A) | |
| 14.15 – 14.45 | Multidisciplinary Tumor Board | |
| | Moderator: Amit Joshi Panelists: <ol style="list-style-type: none"> 1. D. Behera (Pulmonology/Medical Oncology) 2. Kisley Dimri (Radiation Oncology) 3. Manoj Gupta (Radiation Oncology) 4. Kunal Jain (Medical Oncology) 5. Sunil Kumar (Surgical Oncology) 6. Prabhat S. Malik (Medical Oncology) | |

3rd Lung MCMC (Multidisciplinary Cancer Management Course)
A joint initiative of ASCO, ISSLC, PGIMER and TMC in collaboration with Lung Cancer Education Society

DAY TWO - MARCH 25, 2018 (SUNDAY)

| | | |
|----------------------|--|--|
| 14.50 – 15.10 | Industry Sponsored Satellite Symposium 6 (DRL): Nadeem Shoukat & Abhishek Shankar (Chairs) | |
| | Management of Bone Metastasis in Lung Cancer | Gautam Goyal |
| 15.10 – 15.30 | TEA BREAK | |
| 15.30 – 16.00 | Session 13 (Supportive and Palliative Care) | Sushmita Pathy, Rakesh Chopra |
| 15.30 – 15.42 | Prognostic markers for lung cancer | Prabhat Malik |
| 15.42 – 15.45 | Discussion (Q & A) | |
| 15.45 – 15.57 | Early integration of palliative care with standard oncological care | Sushmita Ghoshal |
| 15.57 – 16.00 | Discussion (Q & A) | |
| 16.00 – 16.45 | Session 14 (Lung Cancer in Resource Constrained Setting) | |
| | Panel discussion on challenges related to lung cancer in resource constrained settings: 1) Diagnosis and treatment issues in tuberculosis endemic regions 2) Availability & cost of platforms for predictive biomarker testing 3) Availability and cost of novel targeted therapies and immune check point inhibitors 4) Awareness and adherence to multidisciplinary management | |
| | Moderator: Navneet Singh Panelists: 1. Nalini Gupta (Pathology/Molecular Biology) 2. Deepali Jain (Pathology/Molecular Biology) 3. Sukhpal Kaur (Palliative/Oncological Nursing) 4. Divya Khosla (Radiation Oncology) 5. Prasanta Mohapatra (Pulmonology/Medical Oncology) 6. Valliappan Muthu (Pulmonology/Medical Oncology) | |
| 16.45 – 17.00 | Concluding Remarks & Wrap-up | Navneet Singh, CS Pramesh & Vanessa Sarchet |